Burcin Karasah Erkek

Burcin Karasah Erkek

Auto-generated profile, based on publicly available information

Burcin Karasah Erkek

Ağrı Training and Research Hospital, Clinic of Nuclear Medicine, Ağrı, Türkiye

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2021 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
BEBurcin Karasah Erkek
Burcin Karasah Erkek
ÖÖÖzgür Ömür
Özgür Ömür
SÖSerdar Özkök
Serdar Özkök
BTBurak Turna
Burak Turna
We report 3 patients with COVID-19 findings in 68Ga-PSMA PET/CT taken for staging. The first patient, A 64-year-old man with prostate cancer, who had COVID-19 in November 2020 and whose treatment was completed, was observed to continue with COVID-19 findings in 68Ga-PSMA PET/CT in December 2020 before surgery. Other patients were asymptomatic for the disease. It was determined that a PSMA uptake in the lungs corresponding to the CT findings of COVID-19 had increased in 68Ga-PSMA PET/CT.

3 March 2026 in Annals of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
EÇEsra Çiftçi
Esra Çiftçi
BABurak Akovali
Burak Akovali
HGHatice Sariyildiz Gumusgoz
Hatice Sariyildiz Gumusgoz
BEBurcin Karasah Erkek
Burcin Karasah Erkek
Objective: Pathological upgrading is common in men with ISUP Grade Group (GG) 1 prostate cancer due to sampling limitations. 68 Ga-PSMA-11 PET/CT is promising for characterizing tumor biology. The 5-point PRIMARY score, which considers uptake, focality, and location, has limited data on predicting occult high-grade cancer in GG1 biopsy patients. This study assessed the score’s accuracy in predicting upgrading in GG1 prostate cancer patients with PSA < 20 ng/mL undergoing radical prostatectomy. Materials and methods: This retrospective study included 71 patients with biopsy-proven GG1 prostate adenocarcinoma, PSA < 20 ng/mL, and 68 Ga-PSMA-11 PET/CT performed within 2 months before radical prostatectomy. PRIMARY scores [1–5] were assigned by two blinded nuclear medicine physicians; scores ≥ 4 were considered high-risk. Pathological upgrading was defined as ISUP GG ≥ 2 on prostatectomy specimens. Diagnostic performance was assessed using ROC analysis, and univariate and multivariate logistic regression models were constructed to determine independent predictors of upgrading. Results: Pathological upgrading occurred in 45/71 patients (63.4%). Upgrading rates increased markedly across PRIMARY score categories: 25% for scores ≤ 3, 81.3% for score 4, and 100% for score 5 ( p < 0.001). A PRIMARY score ≥ 4 demonstrated excellent diagnostic performance (AUC = 0.979), with 97.8% sensitivity, 88.5% specificity, 93.6% PPV, 95.6% NPV, and 94.3% accuracy. SUVmax (AUC = 0.944) and PI-RADS ≥ 4 (AUC = 0.721) were also associated with upgrading; however, in multivariate analysis, only the PRIMARY score remained an independent predictor (OR: 19.9; 95% CI: 2.92-135.28; p = 0.002). Conclusion: “The 68 Ga-PSMA-11 PET/CT PRIMARY score was strongly associated with pathological upgrading in this surgically treated cohort of biopsy-confirmed ISUP GG1 patients with PSA < 20 ng/mL undergoing radical prostatectomy. Incorporating PSMA-based intraprostatic pattern analysis could improve the accuracy of preoperative grading, potentially supporting consideration of surgical management rather than definitive radiotherapy when determining the optimal treatment strategy. Prospective multicenter validation is warranted before broader clinical implementation.

4 June 2026 in Molecular Imaging and Radionuclide Therapy
Verified
Journal Article
Open access
PDF file
FAFurkan Avcı
Furkan Avcı
ATAlpay Tunç
Alpay Tunç
BEBurçin Karaşah Erkek
Burçin Karaşah Erkek
AÖAhmet Aydın Özsaran
Ahmet Aydın Özsaran
GSGÜRDENİZ SERİN
GÜRDENİZ SERİN
ZBZeynep Burak
Zeynep Burak
Potential of Lean Body Mass 18F-FDG PET/CT Parameters to Predict Pathologic Findings in Overweight Endometrial Cancer Cases - Molecular Imaging and Radionuclide Therapy

21 October 2025 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
BEBurcin Karasah Erkek
Burcin Karasah Erkek
HGHatice Sariyildiz Gumusgoz
Hatice Sariyildiz Gumusgoz
OSOzgur Sanli
Ozgur Sanli

1 January 2026 in Journal of Clinical and Analytical Medicine
Verified
Journal Article
Closed access
EÇEsra Çiftçi
Esra Çiftçi
BGBurcu Gülbağcı
Burcu Gülbağcı
HGHatice Sarıyıldız Gümüşgöz
Hatice Sarıyıldız Gümüşgöz
BABurak Akovalı
Burak Akovalı
BEBurçin Karasah Erkek
Burçin Karasah Erkek